Subject: =?big5?B?R2xvYmFsU2hhcmUgMy4xOiCu/Kx2pGq+x7PVutOkaL3XpOWl/qTlqHSyzg==?=
Date: Sun, 25 Nov :54 +0800
MIME-Version: 1.0
Content-Type: multipart/
type="text/html";
boundary="----=_NextPart_000_010D_01CDCAFC.479EEF20"
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.
This is a multi-part message in MIME format.
------=_NextPart_000_010D_01CDCAFC.479EEF20
Content-Type: text/
charset="utf-8"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://140.121.140.23/cgi-bin/cdrfb3/gsweb.cgi?ccd=vnbDq1&o=sid=%22G%22.&v=-1
GlobalShare 3.1: =
=E6=B5=B7=E6=B4=8B=E5=A4=A7=E5=AD=B8=E5=8D=9A=E7=A2=A9=E5=A3=AB=E8=AB=96=E6=
=96=87=E5=85=A8=E6=96=87=E7=B3=BB=E7=B5=B1
=E8=A9=B3=E7=9B=AE=E9=A1=AF=E7=A4=BA=E5=
=8D=80=E5=A1=8A
=E7=AC=AC 3 =E7=AD=86
(=E4=BB=A5=E4=BD=9C=E8=80=85=E5=90=8D=E6=9F=A5=E8=A9=A2=E6=
=B5=B7=E6=B4=8B=E5=A4=A7=E5=AD=B8=E5=9C=96=E6=9B=B8=E9=A4=A8=E9=A4=A8=E8=97=
=8F=E7=B3=BB=E7=B5=B1)
(=E4=BB=A5=E4=BD=9C=E8=80=85=E5=90=8D=E6=9F=A5=E8=A9=A2=E5=
=85=A8=E5=9C=8B=E5=9C=96=E6=9B=B8=E6=9B=B8=E7=9B=AE=E8=B3=87=E8=A8=8A=E7=B6=
(=E4=BB=A5=E4=BD=9C=E8=80=85=E5=90=8D=E6=9F=A5=E8=A9=A2=E5=
=85=A8=E5=9C=8B=E5=8D=9A=E7=A2=A9=E5=A3=AB=E7=B3=BB=E7=B5=B1)
=E8=AB=96=E6=96=87=E5=90=8D=E7=A8=B1:
=E6=8E=A2=E8=A8=8E =EF=81=A11,3-Fucosyltransferase =
(FUT4) =E5=9F=BA=E5=9B=A0=E8=AA=98=E5=B0=8E HSP27 =
=E8=A1=A8=E7=8F=BE=E5=B0=8D=E4=BA=BA=E9=A1=9E=E8=82=BA=E8=85=BA=E7=99=8C=E7=
=B4=B0=E8=83=9E=E6=A0=AA=20
=E4=BE=B5=E5=85=A5=E8=88=87=E7=A7=BB=E5=8B=95=E8=83=BD=E5=8A=9B=E4=B9=8B=E5=
=BD=B1=E9=9F=BF
Studies on =EF=81=A11,3-Fucosyltransferase (FUT4) =
Induced HSP27=20
Expression Mediated Cell Invasion and Migration Ability of Human =
Adenocarcinoma A549 Cells
=E7=A0=94=E7=A9=B6=E7=94=9F:
=E6=8C=87=E5=B0=8E=E6=95=99=E6=8E=88:
=E5=AD=B8=E4=BD=8D=E9=A1=9E=E5=88=A5:
=E7=A2=A9=E5=A3=AB
=E5=AD=B8=E6=A0=A1=E5=90=8D=E7=A8=B1:
=E7=B3=BB=E6=89=80=E5=90=8D=E7=A8=B1:
=E9=A3=9F=E5=93=81=E7=A7=91=E5=AD=B8=E7=B3=BB
& & & & & =
=E5=AD=B8=E8=99=9F:
=E7=95=A2=E6=A5=AD=E5=AD=B8=E5=B9=B4=E5=BA=A6:
=E8=AA=9E=E6=96=87=E5=88=A5:
=E4=B8=AD=E6=96=87
=E9=97=9C=E9=8D=B5=E5=AD=97:
=E5=85=A8=E6=96=87=E5=BD=B1=E5=83=8F=E9=80=A3=E7=B5=90:
(=E6=9C=AC=E8=AB=96=E6=96==E5=B0=8D=E6=A0=A1=E5=85=A7=E5=85=
=AC=E9=96=8B)
=E8=AB=96=E6=96=87=E5=85=A8=E6=96=87(pdf)
=E8=AB=96=E6=96=87=E9=A0=81=E6=95=B8:
=E6=91=98=E8=A6=81:
=E4=B8=AD=E6=96=87=E6=91=98=E8=A6=81
=E8=82=BA=E7=99=8C=E9=AB=98=E5=B1=85=E5=9C=8B=E4=BA=BA=E5=8D=81=
=E5=A4=A7=E7=99=8C=E7=97=87=E6=AD=BB=E5=9B=A0=E7=9A=84=E7=AC=AC=E4=B8=80=E4=
=BD=8D=EF=BC=8C=E8=80=8C=E7=99=8C=E7=B4=B0=E8=83=9E=E7=9A=84=E8=BD=89=E7=A7=
=BB=E6=98=AF=E5=B0=8E=E8=87=B4=E8=82=BA=E7=99=8C=E6=AD=BB=E4=BA=A1=E7=8E=87=
=E8=88=87=E9=A0=90=E5=BE=8C=E7=B5=90=E6=9E=9C=E4=B8=8D=E4=BD=B3=E7=9A=84=E4=
=B8=BB=E5=9B=A0=E3=80=82=E5=9B=A0=E6=AD=A4=E4=BA=86=E8=A7=A3=E8=BD=89=E7=A7=
=BB=E9=81=8E=E7=A8=8B=E4=B8=AD=E5=88=86=E5=AD=90=E9=96=93=E8=A8=8A=E6=81=AF=
=E5=82=B3=E9=81=9E=E7=9A=84=E6=A9=9F=E5=88=B6=EF=BC=8C=E4=B8=A6=E6=89=BE=E5=
=87=BA=E6=9C=89=E6=BD=9B=E5=8A=9B=E5=8F=AF=E4=BD=9C=E7=82=BA=E8=82=BA=E7=99=
=8C=E8=BD=89=E7=A7=BB=E7=9A=84=E7=94=9F=E7=89=A9=E6=8C=87=E6=A8=99=EF=BC=8C=
=E5=8F=AF=E8=83=BD=E5=8F=AF=E6=94=B9=E5=96=84=E8=82=BA=E7=99=8C=E6=B2=BB=E7=
=99=82=E7=9A=84=E5=9B=B0=E5=A2=83=E3=80=82=E6=9C=89=E7=A0=94=E7=A9=B6=E6=8C=
=87=E5=87=BA=E8=82=BA=E7=99=8C=E7=97=85=E6=82=A3=E9=AB=94=E5=85=A7=E8=8B=A5=
=E6=9C=89=E5=B2=A9=E8=97=BB=E9=86=A3=E8=BD=89=E7=A7=BB=E9=85=B6=20
4 (Fucosyltransferase 4, FUT4) =
=E7=9A=84=E9=81=8E=E9=87=8F=E8=A1=A8=E7=8F=BE=E6=9C=83=E6=9C=89=E8=BC=83=E5=
=B7=AE=E7=9A=84=E4=BA=94=E5=B9=B4=E5=AD=98=E6=B4=BB=E7=8E=87=E3=80=82=E5=AF=
=A6=E9=A9=97=E5=B0=87=E5=9F=BA=E5=9B=A0=E8=BD=89=E6=AE=96=E5=85=A5=E4=BA=BA=
=E9=A1=9E=E8=82=BA=E8=85=BA=E7=99=8C=E7=B4=B0=E8=83=9E=E6=A0=AA A549 =
=E5=85=A7=E5=BE=8C=E7=99=BC=E7=8F=BE=20
=E7=B4=B0=E8=83=9E=E5=85=A7=E7=86=B1=E4=BC=91=E5=85=8B=E8=9B=8B=E7=99=BD =
27 (Heat shock protein 27, HSP27) =
=E8=A1=A8=E7=8F=BE=E9=87=8F=E5=A2=9E=E5=8A=A0=E3=80=82HSP27=20
=E7=82=BA=E4=B8=80=E7=A8=AE=E5=8A=A9=E7=96=8A=E8=9B=8B=E7=99=BD=EF=BC=8C=E5=
=9C=A8=E7=99=8C=E7=B4=B0=E8=83=9E=E5=85=A7=E5=8F=83=E4=BA=88=E8=A8=B1=E5=A4=
=9A=E7=B4=B0=E8=83=9E=E9=96=93=E7=9A=84=E7=94=9F=E5=8C=96=E5=8F=8D=E6=87=89=
=E3=80=82HSP 27=20
=E5=9C=A8=E7=99=8C=E7=B4=B0=E8=83=9E=E5=85=A7=E7=9A=84=E9=AB=98=E8=A1=A8=E7=
=8F=BE=E5=BD=B1=E9=9F=BF=E7=B4=B0=E8=83=9E=E7=9A=84=E7=94=9F=E9=95=B7=E3=80=
=81=E5=B0=8D=E6=B2=BB=E7=99=82=E7=94=A2=E7=94=9F=E6=8A=97=E6=80=A7=E7=94=9A=
=E8=87=B3=E5=BD=B1=E9=9F=BF=E7=99=8C=E7=B4=B0=E8=83=9E=E7=9A=84=E8=BD=89=E7=
=A7=BB=E8=A1=8C=E7=82=BA=E3=80=82=E6=88=91=E5=80=91=E5=AF=A6=E9=A9=97=E7=B5=
=90=E6=9E=9C=E9=A1=AF=E7=A4=BA =
HSP27=E9=AB=98=E8=A1=A8=E7=8F=BE=E9=87=8F=E7=9A=84 A549-fut4=20
=E7=B4=B0=E8=83=9E=EF=BC=8C=E6=9C=89=E8=BC=83=E4=BD=B3=E7=9A=84=E7=94=9F=E9=
=95=B7=E7=8E=87=E3=80=82=E5=88=A9=E7=94=A8 Wound healing assay =E8=88=87 =
Transwell assay =E9=A1=AF=E7=A4=BA A549-fut4=20
=E7=B4=B0=E8=83=9E=E7=A7=BB=E5=8B=95=E8=83=BD=E5=8A=9B=E8=BC=83=E5=B7=AE=E3=
=80=82=E4=BD=BF=E7=94=A8 Matrigel-transwell assay =
=E8=A7=80=E5=AF=9F=E5=85=A9=E6=A0=AA=E7=B4=B0=E8=83=9E=E7=9A=84=E4=BE=B5=E5=
=85=A5=E8=83=BD=E5=8A=9B=EF=BC=8C=E7=99=BC=E7=8F=BE A549-fut4=20
=E7=B4=B0=E8=83=9E=E8=A1=A8=E7=8F=BE=E5=87=BA=E8=BC=83=E5=84=AA=E7=95=B0=E7=
=9A=84=E4=BE=B5=E5=85=A5=E8=83=BD=E5=8A=9B=E3=80=82A549-fut4=E7=B4=B0=E8=83=
=9E=E5=85=A7 MMP2 =E8=88=87 MMP9 mRNA =
=E8=A1=A8=E7=8F=BE=E9=87=8F=E9=AB=98=E6=96=BC =
A549-mock=E3=80=82=E7=82=BA=E6=8E=A2=E8=A8=8E HSP27=20
=E5=9C=A8=E8=BD=89=E7=A7=BB=E6=99=82=E6=89=80=E6=89=AE=E6=BC=94=E7=9A=84=E8=
=A7=92=E8=89=B2=EF=BC=8C=E5=AF=A6=E9=A9=97=E4=BD=BF=E7=94=A8 RNAi =
=E6=8A=80=E8=A1=93=E6=8A=91=E5=88=B6 HSP27 =E6=96=BC A549-fut4 =
=E7=B4=B0=E8=83=9E=E5=85=A7=E7=9A=84=E8=A1=A8=E7=8F=BE=E3=80=82=E5=AF=A6=E9=
=A9=97=E7=B5=90=E6=9E=9C=E9=A1=AF=E7=A4=BA=E6=B8=9B=E5=B0=91 HSP27 =
=E6=96=BC=20
A549-fut4 =
=E5=85=A7=E7=9A=84=E8=A1=A8=E7=8F=BE=E5=8F=AF=E9=99=8D=E4=BD=8E=E5=85=B6=E7=
=A7=BB=E5=8B=95=E8=88=87=E4=BE=B5=E5=85=A5=E8=83=BD=E5=8A=9B=E3=80=82=E5=AF=
=A6=E9=A9=97=E9=A1=AF=E7=A4=BA=E6=8A=91=E5=88=B6 HSP27 =E6=96=BC =
A549-fut4=E7=B4=B0=E8=83=9E=E5=85=A7=E7=9A=84=E8=A1=A8=E7=8F=BE=E5=BE=8C=EF=
=BC=8CMMP2 =E8=88=87 MMP9=20
mRNA=E4=B9=9F=E9=9A=A8=E4=B9=8B=E4=B8=8B=E9=99=8D=E3=80=82=E9=80=99=E4=BA=
=9B=E5=AF=A6=E9=A9=97=E7=B5=90=E6=9E=9C=E9=A1=AF=E7=A4=BA=EF=BC=8CHSP27 =
=E5=8F=AF=E8=83=BD=E5=85=B7=E6=9C=89=E8=AA=BF=E6=8E=A7=E8=82=BA=E8=85=BA=E7=
=99=8C=E7=B4=B0=E8=83=9E=E8=BD=89=E7=A7=BB=E7=9A=84=E6=BD=9B=E5=8A=9B=EF=BC=
=8C=E5=9B=A0=E6=AD=A4=E6=B8=9B=E5=B0=91 HSP27=20
=E6=96=BC=E8=82=BA=E8=85=BA=E7=99=8C=E7=B4=B0=E8=83=9E=E8=A1=A8=E7=8F=BE=EF=
=BC=8C=E5=8F=AF=E8=83=BD=E6=9C=83=E6=B8=9B=E7=B7=A9=E8=82=BA=E8=85=BA=E7=99=
=8C=E8=BD=89=E7=A7=BB=E8=A1=8C=E7=82=BA=E3=80=82
Lung cancer is the leading cause of mortality in =
Taiwan.=20
Metastasis to secondary sites remains the major cause of lung =
associated death. Hence, more clearly understand the molecular =
mechanisms=20
underlying the metastasis process and to develop novel potential =
biomarker=20
for lung cancer could improve therapeutic treatments. High =
expression=20
level of fucosyltransferase 4 (FUT4) in lung cancer patients =
showed low=20
5-year survival rate. Heat shock protein 27 (HSP27) was =
significantly=20
elevated in FUT4 transfected A549 (A549-fut4) cells. HSP27 is a =
molecular=20
chaperone in cellular response for variety of stresses. Studies =
that HSP 27 have various cellular functions to promote =
differentiation,=20
proliferation, motility and metastasis in cancer cells. Our =
results=20
revealed high induced HSP 27 in A549-fut4 cells have worse =
migration=20
ability by Wound healing assay and Transwell assay. Used=20
Matrigel-transwell assay to observe invasion ability showed that =
A549-fut4=20
has better invasion ability. A549-fut4 has higher MMP2 and MMP9 =
expression than A549-mock. We further used RNAi technique to =
analyze the=20
role of HSP27 in migration and invasion abilities. After HSP27 =
knock-down,=20
migration and invasion abilities of A549-fut4 were greatly =
reduced.=20
Furthermore, we observed MMP2 and MMP9 mRNA expression, we found =
MMP2 and=20
MMP9 mRNA with lower expression after HSP27 knock-down. =
Accordingly, HSP27=20
has potential to modulate lung cancer cell-related process. =
Therefore,=20
knock-down the expression level of HSP27 in lung cancer cells may =
decrease=20
its metastastic power.
=E8=AB=96=E6=96=87=E7=9B=AE=E6=AC=A1:
=E4=B8=AD=E6=96=87=E6=91=98=E8=A6=81& & =
Abstract& & VII
=E5=A3=B9=E3=80=81& & =
=E5=89=8D=E8=A8=80& & 1
=E8=B2=B3=E3=80=81& & =
=E6=96=87=E7=8D=BB=E6=95=B4=E7=90=86& & 3
=E4=B8=80=E3=80=81& & =
=E8=82=BA=E7=99=8C& & 3
(=E4=B8=80)& & =
=E7=BD=B9=E6=82=A3=E8=82=BA=E7=99=8C=E7=9A=84=E5=8D=B1=E9=9A=AA=E5=9B=A0=E5=
=AD=90& & 4
(=E4=BA=8C)& & =
=E8=82=BA=E7=99=8C=E6=B2=BB=E7=99=82& & 4
=E4=BA=8C=E3=80=81& & =E9=86=A3=E5=9F=BA =
(Glycan)& & 5
(=E4=B8=80)& & =
=E5=96=AE=E9=86=A3=E8=88=87=E9=86=A3=E5=9F=BA& & 5
(=E4=BA=8C)& & =
=E9=86=A3=E8=9B=8B=E7=99=BD& & 6
(=E4=B8=89)& & =
=E9=86=A3=E5=9F=BA=E8=88=87=E7=99=8C=E7=97=87& & 6
=E4=B8=89=E3=80=81& & =
=E5=B2=A9=E8=97=BB=E9=86=A3=E8=BD=89=E7=A7=BB=E9=85=B6 =
(Fucosyltransferase)& &=20
(=E4=B8=80)& & =
=E9=B3=A5=E7=B3=9E=E5=98=8C=E5=91=A4=E4=BA=8C=E7=A3=B7=E9=85=B8=E5=B2=A9=E8=
=97=BB=E9=86=A3=E7=94=9F=E5=90=88=E6=88=90 (Guanosine-diphosphate=20
fucose, GDP-Fuc)& & 8
(=E4=BA=8C)& & =
=E5=B2=A9=E8=97=BB=E9=86=A3=E8=BD=89=E7=A7=BB=E9=85=B6=E7=9A=84=E7=B5=90=E6=
=A7=8B& & 9
(=E4=B8=89)& & =
=E5=B2=A9=E8=97=BB=E9=86=A3=E8=BD=89=E7=A7=BB=E9=85=B6=E7=9A=84=E7=A8=AE=E9=
=A1=9E& & 9
=E5=9B=9B=E3=80=81& & =
=E7=86=B1=E4=BC=91=E5=85=8B=E8=9B=8B=E7=99=BD 27 (Heat shock protein =
=E5=8F=83=E3=80=81& & =
=E6=9D=90=E6=96=99=E8=88=87=E6=96=B9=E6=B3=95& & 14
=E4=B8=80=E3=80=81& & =
=E5=AF=A6=E9=A9=97=E6=9D=90=E6=96=99& & 14
(=E4=B8=80)& & =
=E7=B4=B0=E8=83=9E=E5=9F=B9=E9=A4=8A& & 14
(=E4=BA=8C)& & =
=E8=9B=8B=E7=99=BD=E8=B3=AA=E8=90=83=E5=8F=96=E5=8F=8A=E5=AE=9A=E9=87=8F&=
(=E4=B8=89)& & =
=E8=A5=BF=E6=96=B9=E9=BB=9E=E5=A2=A8=E6=B3=95& & 14
(=E5=9B=9B)& & =
=E7=B4=B0=E8=83=9E=E7=94=9F=E9=95=B7=E7=8E=87=E8=88=87=E5=AD=98=E6=B4=BB=E7=
=8E=87& & 15
(=E4=BA=94)& & RNA =
=E8=90=83=E5=8F=96& & 16
(=E5=85=AD)& & =
=E5=8F=8D=E8=BD=89=E9=8C=84=E8=88=87=E5=8D=B3=E6=99=82=E8=BD=89=E9=8C=84=E8=
=81=9A=E5=90=88=E9=85=B6=E9=80=A3=E9=8E=96=E5=8F=8D=E6=87=89 =
(RT-qPCR)& &=20
(=E4=B8=83)& & =
=E5=9F=BA=E5=9B=A0=E9=BB=98=E5=8C=96& & 16
(=E5=85=AB)& & =
=E7=B4=B0=E8=83=9E=E4=BE=B5=E5=85=A5=E8=83=BD=E5=8A=9B=E5=88=86=E6=9E=90&=
(=E4=B9=9D)& & =
=E7=B4=B0=E8=83=9E=E7=A7=BB=E5=8B=95=E8=83=BD=E5=8A=9B=E5=88=86=E6=9E=90 =
(Transwell assay)& &=20
(=E5=8D=81)& & =
=E7=B4=B0=E8=83=9E=E7=A7=BB=E5=8B=95=E8=83=BD=E5=8A=9B=E5=88=86=E6=9E=90 =
(Wound healing assay)& &=20
=E4=BA=8C=E3=80=81& & =
=E5=AF=A6=E9=A9=97=E6=96=B9=E6=B3=95& & 17
(=E4=B8=80)& & =
=E7=B4=B0=E8=83=9E=E5=9F=B9=E9=A4=8A& & 17
(=E4=BA=8C)& & =
=E8=9B=8B=E7=99=BD=E8=B3=AA=E8=90=83=E5=8F=96=E5=8F=8A=E5=AE=9A=E9=87=8F&=
(=E4=B8=89)& & =
=E8=A5=BF=E6=96=B9=E9=BB=9E=E5=A2=A8=E6=B3=95& & 20
(=E5=9B=9B)& & =
=E7=B4=B0=E8=83=9E=E7=94=9F=E9=95=B7=E7=8E=87=E8=88=87=E5=AD=98=E6=B4=BB=E7=
=8E=87& & 26
(=E4=BA=94)& & RNA =
=E8=90=83=E5=8F=96& & 27
(=E5=85=AD)& & =
=E5=8F=8D=E8=BD=89=E9=8C=84=E8=88=87=E5=8D=B3=E6=99=82=E8=BD=89=E9=8C=84=E8=
=81=9A=E5=90=88=E9=85=B6=E9=80=A3=E9=8E=96=E5=8F=8D=E6=87=89 =
(RT-qPCR)& &=20
(=E4=B8=83)& & =
=E5=9F=BA=E5=9B=A0=E9=BB=98=E5=8C=96& & 29
(=E5=85=AB)& & =
=E7=B4=B0=E8=83=9E=E4=BE=B5=E5=85=A5=E8=83=BD=E5=8A=9B=E5=88=86=E6=9E=90&=
(=E4=B9=9D)& & =
=E7=B4=B0=E8=83=9E=E7=A7=BB=E5=8B=95=E8=83=BD=E5=8A=9B=E5=88=86=E6=9E=90 =
(Transwell assay)& &=20
(=E5=8D=81)& & =
=E7=B4=B0=E8=83=9E=E7=A7=BB=E5=8B=95=E8=83=BD=E5=8A=9B=E5=88=86=E6=9E=90 =
(Wound healing assay)& &=20
=E8=82=86=E3=80=81& & =
=E7=B5=90=E6=9E=9C& & 35
(=E4=B8=80)& & A549-fut4 =
=E8=88=87A549-mock=20
=E7=B4=B0=E8=83=9E=E7=94=9F=E9=95=B7=E7=8E=87=E3=80=81=E7=A7=BB=E5=8B=95=E8=
=83=BD=E5=8A=9B=E5=92=8C=E4=BE=B5=E5=85=A5=E8=83=BD=E5=8A=9B=E6=AF=94=E8=BC=
(=E4=BA=8C)& & =E8=A7=80=E5=AF=9FHSP27 =
=E5=9F=BA=E5=9B=A0=E9=BB=98=E5=8C=96=E6=96=BC A549-fut4=20
=E7=B4=B0=E8=83=9E=E5=85=A7=E7=9A=84=E8=A1=A8=E7=8F=BE=E9=87=8F=E5=B0=8D=E5=
=85=B6=E7=A7=BB=E5=8B=95=E8=83=BD=E5=8A=9B=E5=92=8C=E4=BE=B5=E5=85=A5=E8=83=
=BD=E5=8A=9B=E4=B9=8B=E5=BD=B1=E9=9F=BF& & 37
=E4=BC=8D=E3=80=81& & =
=E8=A8=8E=E8=AB=96& & 39
=E9=99=B8=E3=80=81& & =
=E7=B5=90=E8=AB=96& & 43
=E6=9F=92=E3=80=81& & =
=E5=8F=83=E8=80=83=E6=96=87=E7=8D=BB& & 44
=E6=8D=8C=E3=80=81& & =E5=9C=96& =
=E8=AC=9D=E8=BE=AD& & 78
=E5=9C=96=E7=9B=AE=E9=8C=84
=E5=9C=96=E4=B8=80=E3=80=81=E5=88=A9=E7=94=A8=E8=A5=BF=E6=96=B9=
=E9=BB=9E=E5=A2=A8=E6=B3=95=E5=81=B5=E6=B8=AC HSP27 =
=E8=9B=8B=E7=99=BD=E8=B3=AA=E6=96=BC A549-fut4 and A549-mock=20
=E5=85=A9=E6=A0=AA=E7=B4=B0=E8=83=9E=E5=85=A7=E8=A1=A8=E7=8F=BE=E9=87=8F=E3=
=80=82& & 60
=E5=9C=96=E4=BA=8C=E3=80=81=E4=BD=BF=E7=94=A8=E5=8D=B3=E6=99=82=
=E8=81=9A=E5=90=88=E9=85=B6=E9=80=A3=E9=8E=96=E5=8F=8D=E6=87=89=E8=A7=80=E5=
=AF=9F A549-fut4 and A549-mock =
=E5=85=A9=E6=A0=AA=E7=B4=B0=E8=83=9E=E5=85=A7 HSP27 mRNA=20
=E8=A1=A8=E7=8F=BE=E9=87=8F=E7=9A=84=E5=B7=AE=E7=95=B0=E3=80=82& =
=E5=9C=96=E4=B8=89=E3=80=81=E4=BD=BF=E7=94=A8 WST-1 =
=E6=AF=94=E8=BC=83 A549-fut4 and A549-mock =
=E5=85=A9=E6=A0=AA=E7=B4=B0=E8=83=9E=E6=96=BC 24 =E8=88=87 48=20
=E5=B0=8F=E6=99=82=E7=B4=B0=E8=83=9E=E7=94=9F=E9=95=B7=E7=8E=87=E3=80=82&=
=E5=9C=96=E5=9B=9B=E3=80=81=E5=88=A9=E7=94=A8=E5=82=B7=E5=8F=A3=
=E7=99=92=E5=90=88=E8=A9=A6=E9=A9=97=E6=AF=94=E8=BC=83 A549-fut4 =
=E8=88=87 A549-mock =
=E5=85=A9=E6=A0=AA=E7=B4=B0=E8=83=9E=E7=9A=84=E7=A7=BB=E5=8B=95=E8=83=BD=E5=
=8A=9B=E3=80=82& &=20
=E5=9C=96=E4=BA=94=E3=80=81=E5=88=A9=E7=94=A8 =
Transwell assay =E6=AF=94=E8=BC=83 A549-fut4 =E8=88=87 A549-mock=20
=E5=85=A9=E6=A0=AA=E7=B4=B0=E8=83=9E=E7=A7=BB=E5=8B=95=E8=83=BD=E5=8A=9B=E3=
=80=82& & 65
=E5=9C=96=E5=85=AD=E3=80=81=E5=88=A9=E7=94=A8 =
Matrigel-transwell assay =E6=AF=94=E8=BC=83 A549-fut4 =E8=88=87 =
A549-mock=20
=E5=85=A9=E6=A0=AA=E7=B4=B0=E8=83=9E=E4=BE=B5=E5=85=A5=E8=83=BD=E5=8A=9B=E3=
=80=82& & 67
=E5=9C=96=E4=B8=83=E3=80=81=E4=BD=BF=E7=94=A8=E5=8D=B3=E6=99=82=
=E8=81=9A=E5=90=88=E9=85=B6=E9=80=A3=E9=8E=96=E5=8F=8D=E6=87=89=E8=A7=80=E5=
=AF=9F A549-fut4 and A549-mock =
=E5=85=A9=E6=A0=AA=E7=B4=B0=E8=83=9E=E5=85=A7 MMP2 =E5=92=8C MMP9=20
=E8=A1=A8=E7=8F=BE=E9=87=8F=E7=9A=84=E5=B7=AE=E7=95=B0=E3=80=82& =
=E5=9C=96=E5=85=AB=E3=80=81=E5=88=A9=E7=94=A8=E8=A5=BF=E6=96=B9=
=E9=BB=9E=E5=A2=A8=E6=B3=95=E5=81=B5=E6=B8=AC siRNA =E5=B0=8DA549-fut4 =
=E7=B4=B0=E8=83=9E=E5=85=A7 HSP27 =
=E8=9B=8B=E7=99=BD=E8=B3=AA=E8=A1=A8=E7=8F=BE=E9=87=8F=E7=9A=84=E6=8A=91=E5=
=88=B6=E6=83=85=E5=BD=A2=E3=80=82&=20
=E5=9C=96=E4=B9=9D=E3=80=81=E4=BD=BF=E7=94=A8=E5=8D=B3=E6=99=82=
=E8=81=9A=E5=90=88=E9=85=B6=E9=80=A3=E9=8E=96=E5=8F=8D=E6=87=89=E8=A7=80=E5=
=AF=9F siRNA =E5=B0=8D A549-fut4 =E7=B4=B0=E8=83=9E=E5=85=A7 HSP27 mRNA=20
=E8=A1=A8=E7=8F=BE=E9=87=8F=E7=9A=84=E6=8A=91=E5=88=B6=E6=83=85=E5=BD=A2=E3=
=80=82& & 71
=E5=9C=96=E5=8D=81=E3=80=81=E4=BD=BF=E7=94=A8 WST-1 =
=E8=A7=80=E5=AF=9F siRNA =E4=BD=9C=E7=94=A8=E5=BE=8C=E5=B0=8D A549-fut4 =
=E7=B4=B0=E8=83=9E=E5=AD=98=E6=B4=BB=E7=8E=87=E4=B9=8B=E5=BD=B1=E9=9F=BF=E3=
=80=82& &=20
=E5=9C=96=E5=8D=81=E4=B8=80=E3=80=81=E5=88=A9=E7=94=A8 =
Transwell assay =E8=A7=80=E5=AF=9F A549-fut4 =E5=9C=A8 siRNA 24-120=20
=E5=B0=8F=E6=99=82=E7=9A=84=E4=BD=9C=E7=94=A8=E4=B8=8B=E5=B0=8D=E5=85=B6=E7=
=A7=BB=E5=8B=95=E8=83=BD=E5=8A=9B=E4=B9=8B=E5=BD=B1=E9=9F=BF=E3=80=82&nbs=
=E5=9C=96=E5=8D=81=E4=BA=8C=E3=80=81=E5=88=A9=E7=94=A8Matrige=
l-transwell assay =E8=A7=80=E5=AF=9F A549-fut4 =E5=9C=A8 siRNA=20
=E7=9A=84=E4=BD=9C=E7=94=A8=E4=B8=8B=E5=B0=8D=E5=85=B6=E4=BE=B5=E5=85=A5=E8=
=83=BD=E5=8A=9B=E4=B9=8B=E5=BD=B1=E9=9F=BF& & 75
=E5=9C=96=E5=8D=81=E4=B8=89=E3=80=81=E4=BD=BF=E7=94=A8=E5=8D=B3=
=E6=99=82=E8=81=9A=E5=90=88=E9=85=B6=E9=80=A3=E9=8E=96=E5=8F=8D=E6=87=89=E8=
=A7=80=E5=AF=9F=E6=8A=91=E5=88=B6 HSP27 =E5=B0=8D A549-fut4 =
=E7=B4=B0=E8=83=9E=E5=85=A7 MMP2 =E8=88=87 MMP9 mRNA=20
=E8=A1=A8=E7=8F=BE=E9=87=8F=E7=9A=84=E5=BD=B1=E9=9F=BF=E6=83=85=E5=BD=A2=E3=
=80=82& & 77
=E5=8F=83=E8=80=83=E6=96=87=E7=8D=BB:
=E6=9C=B1=E5=B7=BE=E5=BE=AE=E3=80==80=82=E6=8E=A2=E8=
=A8=8EFUT4=E5=8F=8AFUT6=E5=9F=BA=E5=9B=A0=E8=A1=A8=E7=8F=BE=E5=B0=8D=E4=BA=
=BA=E9=A1=9E=E8=82=BA=E7=99=8C=E7=B4=B0=E8=83=9E=E6=A0=AA=E7=9A=84=E5=BD=B1=
=E9=9F=BF=E3=80=82=E5=9C=8B=E7=AB=8B=E4=B8=AD=E8=88=88=E5=A4=A7=E5=AD=B8=E5=
=88=86=E5=AD=90=E7=94=9F=E7=89=A9=E5=AD=B8=E7=A0=94=E7=A9=B6=E6=89=80=E7=A2=
=A9=E5=A3=AB=E5=AD=B8=E4=BD=8D=E8=AB=96=E6=96=87=EF=BC=8C=E5=8F=B0=E4=B8=AD=
=E5=BC=B5=E5=AE=97=E9=8F=97=E3=80==80=82RECK =
=E8=9B=8B=E7=99=BD=E6=8A=97=E8=BD=89=E7=A7=BB=E5=8A=9F=E8=83=BD=E5=8D=80=E4=
=B9=8B=E5=88=86=E6=9E=90=E3=80=82=E5=9C=8B=E7=AB=8B=E4=B8=AD=E5=B1=B1=E5=A4=
=A7=E5=AD=B8=E7=94=9F=E7=89=A9=E9=86=AB=E5=AD=B8=E7=A0=94=E7=A9=B6=E6=89=80=
=E7=A2=A9=E5=A3=AB=E5=AD=B8=E4=BD=8D=E8=AB=96=E6=96=87=EF=BC=8C=E9=AB=98=E9=
=9B=84=E3=80=82
=E8=A1=9B=E7=94=9F=E7=BD=B2=E3=80==80=8299 =
=E5=B9=B4=E8=87=BA=E7=81=A3=E5=9C=B0=E5=8D=80=E4=B8=BB=E8=A6=81=E6=AD=BB=E4=
=BA=A1=E5=8E=9F=E5=9B=A0=E3=80=82=E8=A1=8C=E6=94=BF=E9=99=A2=E8=A1=9B=E7=94=
=9F=E7=BD=B2=E3=80=82=E8=87=BA=E5=8C=97=E3=80=82
Ananthan, J., Goldberg, A. L., and Voellmy, R. =
(1986).=20
Abnormal proteins serve as eukaryotic stress signals and trigger =
activation of heat shock genes. Science 232, 522-524.
Asea, A. (2003). Chaperokine-induced signal =
transduction=20
pathways. Exerc. Immunol. Rev. 9, 25-33.
Augusteyn, R.C. (2004). alpha-crystallin: a review =
structure and function. Clin. Exp. Optom. 87, 356-366.
Avent, N.D. (1997). Human erythrocyte antigen =
expression:=20
its molecular bases. Br. J. Biomed. Sci. 54, 16-37.
Bausero, M.A., Bharti, A., Page, D.T., Perez, K.D., =
J.W., Ordonez, S.L., Asea, E.E., Jantschitsch, C., Kindas-Muegge, =
Ciocca, D., and Asea, A. (2006). Silencing the hsp25 gene =
eliminates=20
migration capability of the highly metastatic murine 4T1 breast=20
adenocarcinoma cell. Tumour bioloy 27, 17-26.
Becker, D.J., and Lowe, J.B. (2003). Fucose: =
biosynthesis=20
and biological function in mammals. Glycobiology 13, =
Boffetta, P. (2004). Epidemiology of environmental =
occupational cancer. Oncogene 23, .
Boffetta, P. (2006). Human cancer from environmental =
pollutants: the epidemiological evidence. Mutat. Res. 608, =
Brockhausen, I. (1999). Pathways of O-glycan =
biosynthesis in=20
cancer cells. Biochim. Biophys. Acta. .
Bruey, J.M., Paul, C., Fromentin, A., Hilpert, S., =
Arrigo,=20
A.P., Solary, E., and Garrido, C. (2000). Differential regulation =
of HSP27=20
oligomerization in tumor cells grown in vitro and in vivo. =
Oncogene 19,=20
Cao, X., Bloomston, M., Zhang, T., Frankel, W.L., =
Jia, G.,=20
Wang, B., Hall, N.C., Koch, R.M., Cheng, H., Knopp, M.V., and Sun, =
(2008). Synergistic antipancreatic tumor effect by simultaneously=20
targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis =
inhibitor. Clin. Cancer Res. 14, .
Chazalet, V., Uehara, K., Geremia, R.A., and Breton, =
(2001). Identification of essential amino acids in the =
Azorhizobium=20
caulinodans fucosyltransferase NodZ. J. Bacteriol. 183, =
Ciocca, D.R., and Calderwood, S.K. (2005). Heat =
proteins in cancer: diagnostic, prognostic, predictive, and =
treatment=20
implications. Cell stress and chaperones 10, 86-103.
Ciocca, D.R., Oesterreich, S., Chamness, G.C., =
McGuire,=20
W.L., and Fuqua, S.A. (1993). Biological and clinical implications =
of heat=20
shock protein 27 (Hsp27). J. Natl. Cancer. 85,.
Concannon, C.G., Orrenius, S., and Samali, A. =
(2001). Hsp27=20
inhibits cytochrome c-mediated caspase activation by sequestering =
pro-caspase-3 and cytochrome c. Gene Expression 9, =
Contessa, J.N., Bhojani, M.S., Freeze, H.H., Ross, =
Rehemtulla, A., and Lawrence, T.S. (2010). Molecular imaging of =
N-linked=20
glycosylation suggests glycan biosynthesis is a novel target for =
therapy. Clin. Cancer Res. 16, .
Cornford, P.A., Dodson, A.R., Parsons, K.F., =
Desmond, A.D.,=20
Woolfenden, A., Fordham, M., Neoptolemos, J.P., Ke, Y., and =
Foster, C.S.=20
(2000). Heat shock protein expression independently predicts =
clinical=20
outcome in prostate cancer. Cancer Res. 60, .
Erkizan, O., Kirkali, G., Yorukoglu, K., and =
Kirkali, Z.=20
(2004). Significance of heat shock protein-27 expression in =
patients with=20
renal cell carcinoma. Urology 64, 474-478.
Esko, J.D., and Selleck, S.B. (2002). Order out of =
assembly of ligand binding sites in heparan sulfate. Annu. Rev. =
Biochem.=20
71, 435-471.
Franck, E., Madsen, O., van Rheede, T., Ricard, G., =
Huynen,=20
M.A., and de Jong, W.W. (2004). Evolutionary diversity of =
vertebrate small=20
heat shock proteins. J. Mol. Evol. 59, 792-805.
Gallegos, B., Perez-Campos, E., Martinez, R., Leyva, =
Martinez, M., Hernandez, R., Pina, S., Hernandez, C., Zenteno, E., =
Hernandez, P. (2010). O-glycosylation expression in fibroadenoma. =
Biochem. Biotechnol. 40, 1-12.
Gibert, B., Eckel, B., Gonin, V., Goldschneider, D., =
Fombonne, J., Deux, B., Mehlen, P., Arrigo, A.P., Clezardin, P., =
Diaz-Latoud, C. (2012). Targeting heat shock protein 27 (HspB1) =
interferes=20
with bone metastasis and tumour formation in vivo. Br. J. =
Goswami, K., Nandeesha, H., Koner, B.C., and =
Nandakumar,=20
D.N. (2007). A comparative study of serum protein-bound sialic =
acid in=20
benign and malignant prostatic growth: possible role of oxidative =
in sialic acid homeostasis. Prostate Cancer P. D. 10, =
Guo, K., Kang, N.X., Li, Y., Sun, L., Gan, L., Cui, =
Gao, M.D., and Liu, K.Y. (2009). Regulation of HSP27 on NF-kappaB =
pathway=20
activation may be involved in metastatic hepatocellular carcinoma =
apoptosis. BMC Cancer 9, 100.
Guo, K., Liu, Y., Zhou, H., Dai, Z., Zhang, J., Sun, =
Chen, J., Sun, Q., Lu, W., Kang, X., and Chen, P. (2008). =
Involvement of=20
protein kinase C beta-extracellular signal-regulating kinase =
1/2/p38=20
mitogen-activated protein kinase-heat shock protein 27 activation =
hepatocellular carcinoma cell motility and invasion. Cancer Sci. =
Hedlund, M., Ng, E., Varki, A., and Varki, N.M. =
(2008).=20
alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma=20
differentiation in vivo. Cancer Res. 68, 388-394.
Hirschberg, C.B. (2001). Golgi nucleotide sugar =
transport=20
and leukocyte adhesion deficiency II. J. Clin. Invest. 108, =
Hoffman, P.C., Mauer, A.M. and Vokes, E.E. (2000). =
cancer. Lancet 355, 479-485.
Homeister, J.W., Thall, A.D., Petryniak, B., Maly, =
Rogers, C.E., Smith, P.L., Kelly, R.J., Gersten, K.M., Askari, =
Cheng, G., Smithson, G., Marks, RM., Misra, A.k., Hindsqual, O., =
Andrian, U.H., and Lowe, J.B. (2001). The alpha (1,3) =
fucosyltransferases=20
FucT-IV and FucT-VII exert collaborative control over =
selectin-dependent=20
leukocyte recruitment and lymphocyte homing. Immunity 15, =
Honda, S., Suzuki, S., and Taga, A. (2003). Analysis =
carbohydrates as 1-phenyl-3-methyl-5-pyrazolone derivatives by=20
capillary/microchip electrophoresis and capillary =
electrochromatography.=20
J. Pharm. Biomed. Anal. 30, .
Kannagi, R. (2004). Molecular mechanism for=20
cancer-associated induction of sialyl Lewis X and sialyl Lewis A=20
expression-The Warburg effect revisited. Glycoconj. J. 20, =
Koo, L.C., and Ho, J.H. (1990). Worldwide =
epidemiological=20
patterns of lung cancer in nonsmokers. Int. J. Epidemiol. 19 Suppl =
Kornfeld, R., and Kornfeld, S. (1985). Assembly of=20
asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54, =
Laemmli, U.K. (1970). Cleavage of structural =
proteins during=20
the assembly of the head of bacteriophage T4. Nature 227, 680-685. =
Ley, K. (2003). The role of selectins in =
inflammation and=20
disease. Trends. Mol. Med. 9, 263-268.
Li, D.Q., Wang, L., Fei, F., Hou, Y.F., Luo, J.M., =
Zeng, R.,=20
Wu, J., Lu, J.S., Di, G.H., Ou, Z.L.,Xia, Q.C., Shen, Z.Z., and =
Shao, Z.M.=20
(2006). Identification of breast cancer metastasis-associated =
proteins in=20
an isogenic tumor metastasis model using two-dimensional gel=20
electrophoresis and liquid chromatography-ion trap-mass =
spectrometry.=20
Proteomics 6, .
Li, M., Song, L., and Qin, X. (2010). Glycan =
changes: cancer=20
metastasis and anti-cancer vaccines. J. Biosci. 35, =
Li, G.P., Wang, H., Lai, Y.K., Chen, S.C., Lin, =
M.C., Lu,=20
G., Zhang, J.F., He, X.G., Qian, C.N., and Kung, H.F. (2011). =
Proteomic=20
profiling between CNE-2 and its strongly metastatic subclone S-18 =
functional characterization of HSP27 in metastasis of =
nasopharyngeal=20
carcinoma. Proteomics 11, .
Lindquist, S., and Craig, E.A. (1988). The =
heat-shock=20
proteins. Annu. Rev. Genet. 22, 631-677.
Little, A.G. (2006).& No nodes is good nodes. =
Thorac. Surg. 82, 4-5.
Lowe, J.B. (2003). Glycan-dependent leukocyte =
adhesion and=20
recruitment in inflammation. Curr. Opin. Cell Biol. 15, 531-538. =
Luhn, K., Laskowska, A., Pielage, J., Klambt, C., =
Ipe, U.,=20
Vestweber, D., and Wild, M.K. (2004). Identification and molecular =
cloning=20
of a functional GDP-fucose transporter in Drosophila melanogaster. =
Cell Res. 301, 242-250.
Luo, Y., and Haltiwanger, R.S. (2005). =
O-fucosylation of=20
notch occurs in the endoplasmic reticulum. J. Biol. Chem. 280,=20
McCurley, R.S., Recinos, A., Olsen, A.S., Gingrich, =
Szczepaniak, D., Cameron, H.S., Krauss, R., and Weston, B.W. =
(1995).=20
Physical maps of human alpha (1,3)fucosyltransferase genes =
FUT3-FUT6 on=20
chromosomes 19p13.3 and 11q21. Genomics 26, 142-146.
Mehlen, P., Preville, X., Chareyron, P., Briolay, =
Klemenz, R., and Arrigo, A.P. (1995). Constitutive expression of =
hsp27, Drosophila hsp27, or human alpha B-crystallin confers =
resistance to=20
TNF- and oxidative stress-induced cytotoxicity in stably =
transfected=20
murine L929 fibroblasts. J. Immunol. 154, 363-374.
Mese, H., Sasaki, A., Nakayama, S., Yoshioka, N., =
Yoshihama,=20
Y., Kishimoto, K., and Matsumura, T. (2002). Prognostic =
significance of=20
heat shock protein 27 (HSP27) in patients with oral squamous cell=20
carcinoma. Oncol. Rep. 9, 341-344.
Miyoshi, E., Uozumi, N., Noda, K., Hayashi, N., =
Hori, M.,=20
and Taniguchi, N. (1997). Expression of alpha1-6 =
fucosyltransferase in rat=20
tissues and human cancer cell lines. Int. J. Cancer 72, =
Molina, J.R., Yang, P., Cassivi, S.D., Schild, S.E., =
Adjei, A.A. (2008). Non-small cell lung cancer: epidemiology, risk =
factors, treatment, and survivorship. Mayo. Clin. Proc. 83, =
Mollicone, R., Cailleau, A., and Oriol, R. (1995). =
Molecular=20
genetics of H, Se, Lewis and other fucosyltransferase genes. =
Transfus.=20
Clin. Biol. 2, 235-242.
Mosser, D.D., and Morimoto, R.I. (2004). Molecular=20
chaperones and the stress of oncogenesis. Oncogene 23, =
Norman, K.E., Anderson, G.P., Kolb, H.C., Ley, K., =
Ernst, B. (1998). Sialyl Lewis(x) (sLe(x)) and an sLe(x) mimetic,=20
CGP69669A, disrupt E-selectin-dependent leukocyte rolling in vivo. =
91, 475-483.
Niittymaki, J., Mattila, P., Roos, C., Huopaniemi, =
Sjoblom, S., and Renkonen, R. (2004). Cloning and expression of =
enzymes involved in the salvage pathway of GDP-L-fucose. Eur. J. =
Biochem.=20
271, 78-86.
Numahata, K., Satoh, M., Handa, K., Saito, S., =
Ohyama, C.,=20
Ito, A., Takahashi, T., Hoshi, S., Orikasa, S., and Hakomori, S.I. =
(2002).=20
Sialosyl-Le(x) expression defines invasive and metastatic =
properties of=20
bladder carcinoma. Cancer 94, 673-685.
Ogawa, J., Inoue, H., and Koide, S. (1996). =
Expression of=20
alpha-1,3-fucosyltransferase type IV and VII genes is related to =
prognosis in lung cancer. Ann. Torac. Surg. 56, 325-329.
Ohtsubo, K., and Marth, J.D. (2006). Glycosylation =
cellular mechanisms of health and disease. Cell 126, =
Oriol, R., Mollicone, R., Cailleau, A., Balanzino, =
L., and=20
Breton, C. (1999). Divergent evolution of fucosyltransferase genes =
vertebrates, invertebrates, and bacteria. Glycobiology 9, 323-334. =
Patsos, G., Hebbe-Viton, V., Robbe-Masselot, C., =
Masselot,=20
D., San Martin, R., Greenwood, R., Paraskeva, C., Klein, A., =
Graessmann,=20
M., Michalski, J.C. Gallagher,T., and Corfield, A. (2009). =
O-glycan=20
inhibitors generate aryl-glycans, induce apoptosis and lead to =
inhibition in colorectal cancer cell lines. Glycobiology 19,=20
Paulson, J.C., and Colley, K.J. (1989).=20
Glycosyltransferases. Structure, localization, and control of cell =
type-specific glycosylation. J. Biol. Chem. 264, =
Pfister, D.G., Johnson, D.H., Azzoli, C.G., Sause, =
Smith, T.J., Baker, S., Jr., Olak, J., Stover, D., Strawn, J.R., =
Turrisi,=20
A.T., Somefield, M.R. (2004). American Society of Clinical =
Oncology=20
treatment of unresectable non-small-cell lung cancer guideline: =
2003. J. Clin. Oncol. 22, 330-353.
Potti, A., Mukherjee, S., Petersen, R., Dressman, =
Bild, A., Koontz, J., Kratzke, R., Watson, M.A., Kelley, M., =
Ginsburg,=20
G.S, West, M., Harpole, JR., and Nevins, JR. (2006). A genomic =
strategy to=20
refine prognosis in early-stage non-small-cell lung cancer. N. =
Engl. J.=20
Med. 355, 570-580.
Reis, C.A., Osorio, H., Silva, L., Gomes, C., and =
David, L.=20
(2010). Alterations in glycosylation as biomarkers for cancer =
detection.=20
J. Clin. Pathol. 63, 322-329.
Rocchi, P., So, A., Kojima, S., Signaevsky, M., =
Beraldi, E.,=20
Fazli, L., Hurtado-Coll, A., Yamanaka, K., and Gleave, M. (2004). =
shock protein 27 increases after androgen ablation and plays a=20
cytoprotective role in hormone-refractory prostate cancer. Cancer =
Res. 64,=20
Samali, A., Robertson, J.D., Peterson, E., Manero, =
F., van=20
Zeijl, L., Paul, C., Cotgreave, I.A., Arrigo, A.P., and Orrenius, =
(2001). Hsp27 protects mitochondria of thermotolerant cells =
against=20
apoptotic stimuli. Cell Stress and Chaperones 6, 49-58.
Schachter, H. (2000). The joys of HexNAc. The =
synthesis and=20
function of N- and O-glycan branches. Glycoconj. J. 17, =
Song, H.Y., Liu, Y.K., Feng, J.T., Cui, J.F., Dai, =
Zhang, L.J., Feng, J.X., Shen, H.L., and Tang, Z.Y. (2006). =
Proteomic=20
analysis on metastasis-associated proteins of human hepatocellular =
carcinoma tissues. J. Cancer Res. Clin. Oncol. 132, =
Takada, A., Ohmori, K., Yoneda, T., Tsuyuoka, K., =
Hasegawa,=20
A., Kiso, M., and Kannagi, R. (1993). Contribution of carbohydrate =
antigens sialyl Lewis A and sialyl Lewis X to adhesion of human =
cells to vascular endothelium. Cancer Res. 53, 354-361.
Tian, T., Hao, J., Xu, A., Luo, C., Liu, C., Huang, =
Xiao, X., and He, D. (2007). Determination of =
metastasis-associated=20
proteins in non-small cell lung cancer by comparative proteomic =
analysis.=20
Cancer Sci. 98, .
Tissieres, A., Mitchell, H. K., and Tracy, U. M. =
(1974).=20
Protein synthesis in salivary glands of Drosophila melanogaster: =
relation=20
to chromosome puffs. J. Mol. Biol. 84, 389-398.
Tonetti, M., Sturla, L., Bisso, A., Benatti, U., and =
Flora, A. (1996). Synthesis of GDP-L-fucose by the human FX =
protein. J.=20
Biol. Chem. 271, .
Tsan, M.F., and Gao, B. (2004). Cytokine function of =
shock proteins. Am. J. Physiol. Cell Physiol. 286, =
Ugorski, M., and Laskowska, A. (2002). Sialyl =
Lewis(a): a=20
tumor-associated carbohydrate antigen involved in adhesion and =
metastatic=20
potential of cancer cells. Acta. Biochim. Pol. 49, =
Vineis, P., Airoldi, L., Veglia, F., Olgiati, L.,=20
Pastorelli, R., Autrup, H., Dunning, A., Garte, S., Gormally, E., =
Hainaut,=20
P., Malaveille ,C., Matullo, G., Peluso, M., Overvad, K., =
Tjonneland, A.,=20
Clavel-Chapelon, F., Boeing, H., Krogh, V., Palli, D., Panico, S., =
Tumino,=20
R., Bueno-De-Mesquita, B., Peeters, P., Berglund, G., Hallmans, =
Saracci, R., and Riboli, E. (2005). Environmental tobacco smoke =
and risk=20
of respiratory cancer and chronic obstructive pulmonary disease in =
smokers and never smokers in the EPIC prospective study. B. M. J. =
Waetzig, G.H., Chalaris, A., Rosenstiel, P., =
Suthaus, J.,=20
Holland, C., Karl, N., Valles Uriarte, L., Till, A., Scheller, J., =
Grotzinger, J., Schreiber, S., Rose-John, S., and Seegert, D. =
(2010).=20
N-linked glycosylation is essential for the stability but not the=20
signaling function of the interleukin-6 signal transducer =
glycoprotein=20
130. J. Biol. Chem. 285, .
Wang, Y., and Spellman, M.W. (1998). Purification =
characterization of a GDP-fucose:polypeptide fucosyltransferase =
Chinese hamster ovary cells. J. Biol. Chem. 273, =
Wang, A., Liu, X., Sheng, S., Ye, H., Peng, T., Shi, =
Crowe, D.L., and Zhou, X. (2009). Dysregulation of heat shock =
protein 27=20
expression in oral tongue squamous cell carcinoma. BMC Cancer 9, =
Wei, L., Liu, T.T., Wang, H.H., Hong, H.M., Yu, =
A.L., Feng,=20
H.P., and Chang, W.W. (2011). Hsp27 participates in the =
maintenance of=20
breast cancer stem cells through regulation of =
epithelial-mesenchymal=20
transition and nuclear factor-kappaB. B. C. R. 13, R101.
Whitelock, J.M., Murdoch, A.D., Iozzo, R.V., and =
Underwood,=20
P.A. (1996). The degradation of human endothelial cell-derived =
perlecan=20
and release of bound basic fibroblast growth factor by =
stromelysin,=20
collagenase, plasmin, and heparanases. J. Biol. Chem. 271,=20
Yan, M., Xu, Q., Zhang, P., Zhou, X.J., Zhang, Z.Y., =
Chen, W.T. (2010). Correlation of NF-kappaB signal pathway with =
metastasis of human head and neck squamous cell carcinoma. BMC =
Cancer 10,=20
Ye, H., Wang, A., Lee, B.S., Yu, T., Sheng, S., =
Peng, T.,=20
Hu, S., Crowe, D.L., and Zhou, X. (2008). Proteomic based =
identification=20
of manganese superoxide dismutase 2 (SOD2) as a metastasis marker =
for oral=20
squamous cell carcinoma. Cancer Genomics Proteomics 5, =
Yeung, S.J., Pan, J., and Lee, M.H. (2008). Roles of =
MYC and HIF-1 in regulating glycolysis - the seventh hallmark of =
cancer.=20
Cell Mol. Life Sci. 65, .
Zhao, Y., Sato, Y., Isaji, T., Fukuda, T., =
Matsumoto, A.,=20
Miyoshi, E., Gu, J., and Taniguchi, N. (2008). Branched N-glycans =
regulate=20
the biological functions of integrins and cadherins. FEBS J. 275,=20
Zhu, Z., Xu, X., Yu, Y., Graham, M., Prince, M.E., =
T.E., and Sun, D. (2010). Silencing heat shock protein 27 =
decreases=20
metastatic behavior of human head and neck squamous cell cancer =
cells in=20
vitro. Mol. Pharm. 7, .
Zhuang, H., Jiang, W., Cheng, W., Qian, K., Dong, =
W., Cao,=20
L., Huang, Q., Li, S., Dou, F., and Chiu, J.F. (2010). =
Down-regulation of=20
HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced =
apoptosis.=20
Lung Cancer 68, 27-38.
&&&&&&&&&&&=
&&&&&&&&&&&&n=
&&&&&&&&&&&&nb=
&&&&&&&&&&&&nbs=
p;&&&&&&&&&&&&nbsp=
;&&&&&&&&&&&&=
&&&&&&&&&&&&&=
&&&&&&&&&&&&n=
&&&&&&&&&&&&nb=
&&&&&&&&=20
=E9=A0=90=E8=A6=BD=E5=8F=8A=E8=BC=B8=E5=87=BA=E6=AA=A2=E7=B4=A2=
=E7=B5=90=E6=9E=9C
=E8=A8=98=E9=8C=84
=E6=AC=84=E4=BD=8D
=E6=9C=AC=E9=A0=81 1 =E7=AD=86
=E8=A8=98=E9=8C=84 3 =E8=87=B3 6
=E9=81=B8=E6=93=87=E4=B9=8B=E8=A8=98=E9=8C=84
=E6=A8=99=E9=A1=8C
=E5=85=A8=E9=83=A8=E6=AC=84=E4=BD=8D
=E7=80=8F=E8=A6=BD=E5=99=A8=E6=9C=AA=E8=83=BD=E6=94=AF=E6=
=8F=B4javascript=EF=BC=8C=E8=AB=8B=E9=BB=9E=E9=81=B8=E9=80=99=E8=A3=A1
Chicago Style
CNS-13611 Style
EndNote Style
&e-mail =E5=9C=B0=E5=9D=80
&e-mail =E6=A8=99=E9=A1=8C
=E7=B3=BB=E7=B5=B1=E8=A6=8F=E5=8A=83=EF=BC=9A=E6=B5=B7=E6=B4=8B=
=E5=A4=A7=E5=AD=B8=E5=9C=96=E6=9B=B8=E9=A4=A8=E7=B3=BB=E7=B5=B1=E8=A3=
=BD=E4=BD=9C=EF=BC=9A=E9=A3=9B=E8=B3=87=E5=BE=97=E8=B3=87=E8=A8=8A=E6=9C=89=
=E9=99=90=E5=85=AC=E5=8F=B8
2012 =E5=B9=B4 11 =E6=9C=88 25 =
=E6=97=A5=20
------=_NextPart_000_010D_01CDCAFC.479EEF20
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://140.121.140.23/cdrfb3/images/goprev.gif
R0lGODlhNgAXAOZLAPb29vLy8vn6+uXl5eDg4P39/Pr6+unp6f39/f38/ODf4Pr5+vLz8uDf3+nq
6erp6fPy8uXk5d/g4P38/ff29vb299vb2tva2uXl5Orp6tva29/f4Pn5+vPz8vz9/erq6vr5+fLy
89vb2+Tk5eTl5eDg3/r6+fLz8+rq6fz8/enq6trb2tra2tra2/b399rb2/Pz8+Tl5Pn6+e7v7vb3
9uTk5N/g3/Py8+Xk5O/u7svLy9/f3/f39svLzNHR0O7u79XV1dDR0Pf299bW1unp6u7u7vHx8eLi
4oiIiGZmZv///////wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5
BAEAAEsALAAAAAA2ABcAAAf/gEtLSISFhoeIiYqLh4KCSDpKkpOUlZaXmJlKPUiOgz5GoaKjpKWm
p6hGQZ2OSENHsLGys7S1trdHQKyPLRoWLSsaLCwWwRYiIhcXSRcvGiLOIixJ1NXWSSssIhrKLRbf
Kxe7gwoSBBINDQQK7OcSGwQESQ0KGyXr6vH3O0kEDTYN3jWwV8KGBAUl6jUYh2REjBoYBgwgMSCC
RQwjRkQgkYRiBAwxKOIYMOIatQE4apCsGPHjAAwkGKr4QOTABwcZUBxA4UAFipsZkmR4QJQoTgcf
kjy4eUCF0KYHDjw44OBABgcopjIswpXrjK5FfoDNcQ0sV5NJzIL92pXhCQYB6uDCgBAiBAS6dE8E
SBIgAAQYDODe6LCXQQgGHTokIdwXAtwTJyDE7XCDYQUKAChgBpAZAA0XACpkThKaMw/QogGgLd25
Ag3OAIQAcMHQBAgBCwwsEGBChgzeuheASCJAtwABHAwY4CAgiQnhBpoLALEgtwETxzlwALGcYQEE
CDxMAD9hQooEKVIgGJ+kQIEJHjwkSCC/AFr5Cb67z5/ifQIEDGliSRICEiiJgQJKEqAmaFkzSTWV
UJOgEgtOaOGFlFSI4YYJasjhh5cwxMiIJJZYiCcopqjiiiy26OKLMMYo44w01mjjjTEGAgA7
------=_NextPart_000_010D_01CDCAFC.479EEF20
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://140.121.140.23/cdrfb3/images/main.gif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------=_NextPart_000_010D_01CDCAFC.479EEF20
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://140.121.140.23/cdrfb3/images/browse.gif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------=_NextPart_000_010D_01CDCAFC.479EEF20
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://140.121.140.23/cdrfb3/images/gonext.gif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==
------=_NextPart_000_010D_01CDCAFC.479EEF20
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://140.121.140.23/cdrfb3/images/goto.gif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------=_NextPart_000_010D_01CDCAFC.479EEF20
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://140.121.140.23/cdrfb3/images/preview.gif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------=_NextPart_000_010D_01CDCAFC.479EEF20
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://140.121.140.23/cdrfb3/images/save.gif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------=_NextPart_000_010D_01CDCAFC.479EEF20
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://140.121.140.23/cdrfb3/images/email.gif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------=_NextPart_000_010D_01CDCAFC.479EEF20
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://140.121.140.23/cdrfb3/images/bgs.gif
R0lGODlhAQABAIAAAAAAAAAAACH5BAEAAAAALAAAAAABAAEAQAICRAEAOw==
------=_NextPart_000_010D_01CDCAFC.479EEF20
Content-Type: application/octet-stream
Content-Transfer-Encoding: quoted-printable
Content-Location: http://140.121.140.23/cdrfb3/styles.css?v=.0
BACKGROUND-POSITION: BACKGROUND-ATTACHMENT: =
BACKGROUND-IMAGE: url(images/bgs.gif); SCROLLBAR-SHADOW-COLOR: #add373; =
SCROLLBAR-3DLIGHT-COLOR: #add373; SCROLLBAR-ARROW-COLOR: #add373; =
SCROLLBAR-TRACK-COLOR: # BACKGROUND-REPEAT: no- =
SCROLLBAR-DARKSHADOW-COLOR: # SCROLLBAR-BASE-COLOR: #fcfaed
FONT-SIZE: 12 BORDER-LEFT-COLOR: BORDER-BOTTOM-COLOR: =
BORDER-TOP-COLOR: BORDER-RIGHT-COLOR: ivory
BORDER-RIGHT: #7d4900 1 BORDER-TOP: #7d4900 1 =
FONT-SIZE: 10 MARGIN: 1 BORDER-LEFT: #7d4900 1 COLOR: =
BORDER-BOTTOM: #7d4900 1 BACKGROUND-COLOR: white
.inputbox {
BORDER-RIGHT: #7d4900 1 BORDER-TOP: #7d4900 1 =
FONT-SIZE: 10 MARGIN: 1 BORDER-LEFT: #7d4900 1 COLOR: =
BORDER-BOTTOM: #7d4900 1 BACKGROUND-COLOR: white
FONT-SIZE: 9pt
COLOR: sienna
.headline {
MARGIN: 4pt 40pt 4pt 5 FONT: bold 19pt "?????" COLOR: =
#7d4900; LETTER-SPACING: -1pt
.headline {
MARGIN: 4pt 40pt 4pt 5 FONT: bold 16px Arial, Helvetica, sans- =
COLOR: #000000; LETTER-SPACING: -1pt
.mainth A {
COLOR: TEXT-DECORATION: none
.mainth A:hover {
COLOR: #ff8844
BORDER-TOP: #ffffff 1 FONT-SIZE: 12 BORDER-LEFT: #ffffff =
1 COLOR: # LINE-HEIGHT: 22 BORDER-BOTTOM: #ffffff 1px =
BACKGROUND-COLOR: #666666; BORDER-RIGHT-WIDTH: 1 =
BORDER-RIGHT-COLOR: #ffffff
.maintd1 {
BORDER-TOP-WIDTH: 1 BORDER-LEFT-WIDTH: 1 FONT-SIZE: 11 =
BORDER-LEFT-COLOR: # BORDER-TOP-COLOR: # LINE-HEIGHT: =
16 BORDER-BOTTOM: #cccccc 1 BACKGROUND-COLOR: #f3f3f3; =
BORDER-RIGHT-WIDTH: 1 BORDER-RIGHT-COLOR: #cccccc
.maintd0 {
BORDER-TOP-WIDTH: 1 BORDER-LEFT-WIDTH: 1 FONT-SIZE: 11 =
BORDER-LEFT-COLOR: # BORDER-TOP-COLOR: # LINE-HEIGHT: =
16 BORDER-BOTTOM: #cccccc 1 BACKGROUND-COLOR: # =
BORDER-RIGHT-WIDTH: 1 BORDER-RIGHT-COLOR: #cccccc
.mainlink:link {
COLOR: #663300; TEXT-DECORATION: underline
.mainlink:visited {
COLOR: #663300; TEXT-DECORATION: underline
.mainlink:hover {
COLOR: #ff6600; TEXT-DECORATION: none
.mainlink:active {
COLOR: #ff6600; TEXT-DECORATION: none
.smallti {
FONT-SIZE: 80%
.inverse {
COLOR: BACKGROUND-COLOR: #ffffc0
.redfont {
COLOR: red
.redbold {
FONT-WEIGHT: COLOR: red
.graphchar {
FONT-SIZE: 30 COLOR: FONT-FAMILY: Webdings
.graphchar {
FILTER: dropshadow(color=3Dsilver,offx=3D1,offy=3D1,enabled=3D1)
.heading {
FONT-WEIGHT: FONT-SIZE: 14 COLOR: FONT-STYLE: italic
.heading {
FILTER: dropshadow(color=3Dsilver,offx=3D2,offy=3D1,enabled=3D1)
.scanvalue_field {
WIDTH: 90%
.scanvalue_div {
WIDTH: 100%; BACKGROUND-COLOR: #faf0f2
.scanvalue_field LEGEND {
BORDER-RIGHT: #999 1 PADDING-RIGHT: 4 BORDER-TOP: #ccc 1px =
PADDING-LEFT: 4 FONT-WEIGHT: FONT-SIZE: 12 =
BACKGROUND: # PADDING-BOTTOM: 4 BORDER-LEFT: #ccc 1 =
PADDING-TOP: 4 BORDER-BOTTOM: #999 1 FONT-FAMILY: Verdana, =
Arial, sans-serif
.scanfield_field {
WIDTH: 70%
.scanfield_div {
WIDTH: 100%; BACKGROUND-COLOR: #faf0f2
.scanfield_field LEGEND {
BORDER-RIGHT: #999 1 PADDING-RIGHT: 4 BORDER-TOP: #ccc 1px =
PADDING-LEFT: 4 FONT-WEIGHT: FONT-SIZE: 12 =
BACKGROUND: # PADDING-BOTTOM: 4 BORDER-LEFT: #ccc 1 =
PADDING-TOP: 4 BORDER-BOTTOM: #999 1 FONT-FAMILY: Verdana, =
Arial, sans-serif
.detailformat_field {
WIDTH: 80%
.detailformat_div {
WIDTH: 100%; BACKGROUND-COLOR: #faf0f2
.detailformat_field LEGEND {
BORDER-RIGHT: #999 1 PADDING-RIGHT: 4 BORDER-TOP: #ccc 1px =
PADDING-LEFT: 4 FONT-WEIGHT: FONT-SIZE: 12 =
BACKGROUND: # PADDING-BOTTOM: 4 BORDER-LEFT: #ccc 1 =
PADDING-TOP: 4 BORDER-BOTTOM: #999 1 FONT-FAMILY: Verdana, =
Arial, sans-serif
.fontimg {
POSITION: absolute
------=_NextPart_000_010D_01CDCAFC.479EEF20
Content-Type: application/octet-stream
Content-Transfer-Encoding: quoted-printable
Content-Location: http://140.121.140.23/cdrfb3/cdr_ground.js
// GlobalShare 3.1 Web=0A=
// Copyright , FlySheet Information Services, Inc.=0A=
// cdr_ground.js=0A=
Web Form JavaScript=0A=
Launch: 10/29/07=0A=
Revise: 10/29/07=0A=
try{ if (clearok=3D=3D1){cclean();}}catch (err) {}=0A=
function cclean() {=0A=
var f =3D document.forms[0];=0A=
if (f.elements[ckfield]){=0A=
f.elements[ckfield][0].checked =3D=0A=
f.elements[ckfield][1].checked =3D=0A=
------=_NextPart_000_010D_01CDCAFC.479EEF20--